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Involved site lymphoma radiotherapy clinical target volumes (CTV) require expansion in the absence of
treatment-position pre-chemotherapy PET-CT. This prospective imaging study evaluates CTV contouring
for axillary lymphoma using diagnostic imaging compared with co-registered treatment-position PET-CT.
Generous expansion axially and cranio-caudally is required to encompass pre-chemotherapy disease
without treatment-position pre-chemotherapy PET-CT.
 2018 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
There has been considerable progress in reducing radiotherapy
target volumes in lymphoma patients to minimise late complica-
tions whilst maintaining local control [1–3]. The concept of
involved node radiotherapy (INRT) was developed with the aim
of treating only prior sites of lymph node involvement [1]. INRT
requires the acquisition of a pre-chemotherapy Fluorine-18 fluo-
rodeoxyglucose (FDG) positron emission tomography – computed
tomography (PET-CT) scan in the radiotherapy treatment position
with the use of the relevant radiotherapy immobilisation devices
and subsequent co-registration to the post-chemotherapy radio-
therapy planning CT scan. However, few centres routinely acquire
a pre-chemotherapy FDG PET-CT in the potential radiotherapy
treatment position [4]. The concept of involved site radiotherapy
(ISRT) has been developed by the International Lymphoma Radio-
therapy Oncology Group (ILROG) [2,3]. The ILROG guidelines pro-
vide guidance on delineating a clinical target volume (CTV) to
encompass pre-chemotherapy disease, modified to anatomicalboundaries, with an additional expansion to account for any uncer-
tainty in defining pre-chemotherapy disease (including the quality
and position of pre-chemotherapy imaging, response to
chemotherapy, knowledge of potential subclinical extent, volume
changes since imaging, proximity to critical structures) with
modification to anatomical boundaries. This CTV expansion is
essentially based upon clinical judgement [4]. The UK National
Cancer Research Institute Lymphoma Radiotherapy Group [5] also
developed ISRT guidelines and attempted to quantify the required
CTV expansion specifying 1.5 cm craniocaudally in the direction of
lymphatic spread with no axial expansion.
There is little data to guide the necessary CTV expansion to
account for the absence of pre-chemotherapy imaging in the radio-
therapy position. We have performed a prospective imaging study
aiming to quantify the required CTV expansion, and have previ-
ously reported results for patients requiring head and neck radio-
therapy [6]. Axillary radiotherapy is a less common scenario
although CTV delineation is particularly challenging compared
with the head and neck region, with differences in arm position
between scans and less well defined anatomical landmarks. Here,
we report data from patients in our imaging study with axillary
nodal disease.
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2.1. Study outline
This is a report on patients with axillary nodal disease
included within a prospective single centre imaging study. Inclu-
sion criteria were: age 18 years old, histologically proven Hodg-
kins Lymphoma (HL) or high grade non-Hodgkins Lymphoma
(NHL), World Health Organization Performance status 0–2, Ann
Arbor Stage I/II disease based upon clinical examination and
any radiology investigations previously performed, residual dis-
ease in situ after biopsy, PET-CT staging not yet performed, clin-
ical decision that sequential chemotherapy and radiotherapy will
be the recommended treatment if stage I/II disease is confirmed
on subsequent PET-CT staging. This study was approved by the
Research Ethics Committee. Trial registration: ISRCTN Registry:
ISRCTN46587767.
A total of 19 patients provided written informed consent and
were recruited between October 2013 and January 2016; 3 of the
patients who subsequently received chemotherapy and radiother-
apy had axillary nodal disease.2.2. PET-CT imaging
A 5-point thermoplastic immobilisation mask was fabricated
prior to PET-CT acquisition, with arms by sides. FDG PET-CT
imaging was performed as previously described [6]. A diagnostic
half-body PET-CT with arms up on a soft head support was initially
performed 60 min following a 400 MBq injection of FDG intra-
venously; if patients were not able to tolerate the arms up position
an arms down position was used. A dedicated contrast-enhanced
PET-CT of the axillary region was then acquired with the immobi-
lization mask in place with a radiotherapy head rest, arms down
(3–4 bed positions, 2 min per bed position).2.3. Radiotherapy CT planning scan
The thermoplastic mask fabricated for the pre-chemotherapy
PET-CT scan was fitted to assess whether the fit remained optimal.
If this was not the case, a new thermoplastic mask was made
attempting to maintain a similar neck position. The CT planning
scan was acquired with intravenous contrast and 2 or 3 mm slice
thickness (dependent upon institutional protocols at the time).2.4. CTV contouring
Contouring was performed by an experienced radiation
oncologist with access to clinical data and diagnostic imaging. To
minimise recall, a minimum two week interval was mandated
prior to contouring for each individual patient using different
methods.2.5. Contouring using side-by-side assessment of PET-CT acquired in
diagnostic position (CTVdiagPET)
A post-chemotherapy CTV aiming to encompass initially
involved lymphoma tissue was contoured using the pre-
chemotherapy diagnostic position PET-CT by side-by-side assess-
ment (blinded to treatment position PET-CT), taking into account
changes in lymphoma volume and anatomical changes, whilst
accounting for anatomical boundaries. To allow quantification of
the ‘errors’ introduced by contouring without optimal co-
registered imaging, no additional CTV expansion was undertaken
(CTVdiagPET).2.6. Contouring using co-registration of PET-CT acquired in
radiotherapy position to planning CT scan (CTVINRT)
Contouring was performed according to the principles of the
ILROG guidelines [2,3] and as previously described [6] (CTVINRT).
The contrast-enhanced pre-chemotherapy PET-CT acquired in the
radiotherapy position was used to manually contour a gross
tumour volume (GTV). Manual rigid registration was undertaken
matching to the chest wall and local soft-tissue in the region of
the delineated GTV using Mirada RTx v1.4 software (Mirada Med-
ical, Oxford, UK).
3. Data analysis
3.1. Assessment of superior and inferior CTV extent
Distance between the superior slices of the CTVINRT and
CTVdiagPET was recorded. Distance was similarly recorded for infe-
rior slices.
3.2. Positional analysis
Positional metrics were used to compare CTVs in the axial plane
as previously described [6,7]. The most superior and inferior over-
lapping slices of the CTVs (CTVINRT and CTVdiagPET) were defined as
the limits of the volume, excluding differences in the superior-
inferior CTV length from influencing positional metrics. Positional
metrics were calculated using ImSimQA software (v3.1.5, OSL,
Shrewsbury, UK): Mean distance to conformity (MDC); Centre of
gravity distance (CGD); DICE index; conformality index (CI); sensi-
tivity index (Se. Idx). For the CTVINRT and CTVdiagPET axial plane
comparison, the Se. Idx. calculated the overlap between CTVdiagPET
and CTVINRT as a percentage of the volume of CTVINRT.
3.3. Statistics
Linear mixed effects models were used to determine the signif-
icance of the differences between CTVINRT and CTVdiagPET [8]. A sig-
nificant q-value was considered to be q < 0.05.
4. Results
3 patients who entered the study subsequently received axillary
radiotherapy. Patients 1 and 3 had Hodgkin’s lymphoma and
patient 2 diffuse large B cell lymphoma; age range 21–70 years;
mean pre-chemotherapy GTV 78 cm3 (range 33–141). Each patient
had received chemotherapy prior to planning for radiotherapy.
Patient 1 had the diagnostic PET-CT scan arms down due to dis-
comfort maintaining an arms-up position. (Fig. 1 provides an
example of CTVINRT and CTVdiagPET in axial and coronal images.)
4.1. Intra-observer variation in CTV generation
Intra-observer variation in delineating CTVINRT and CTVdiagPET on
3 occasions for each patient are summarised in Table 1. Variation
CTV extent was large for CTVdiagPET, with a mean of 7 mm superi-
orly and 13 mm inferiorly. By contrast, CTVINRT varied by only a
single CT slice (2–3 mm) superiorly and inferiorly. Similarly,
CTVINRT was significantly more reproducible in the axial plane
compared with CTVdiagPET for all positional metrics.
4.2. Comparison of CTVINRT and CTVdiagPET: Superior and inferior extent
Table 2 summarises CTV volumes and differences in the supe-
rior and inferior boundaries of CTVINRT and CTVdiagPET. Overall vol-
Fig. 1. Comparison of cranio-caudal length of CTVINRT and CTVdiagPET in the coronal plane in a patient with stage I diffuse large B cell lymphoma of left axilla treated with 3
cycles of chemotherapy followed by radiotherapy. In coronal plane A) represents pre-chemotherapy FDG PET-CT acquired in the routine arms up diagnostic position, B)
represents pre-chemotherapy PET-CT in treatment position with a radiotherapy mask, C) planning CT scan with CTVINRT (blue) (contoured using co-registered pre-
chemotherapy radiotherapy treatment-position PET-CT) and CTVdiagPET (red) (contoured using side-by-side assessment of diagnostic PET-CT). In the axial plane D) and E)
show pre-chemotherapy FDG PET-CT in arms up diagnostic position and treatment position arms down respectively, E) planning CT scan with CTVINRT (blue) and CTVdiagPET
(red). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Table 1
Intra-observer variation in the delineation of CTVINRT and CTVdiagPET.
Patient CI MDC (mm) CGD (mm) DICE Superior and inferior extent
variation (mm)
Superior Inferior
CTVINRT 1 0.59 4.60 3.24 0.78 0 2
2 0.61 4.72 3.32 0.83 3 3
3 0.65 3.86 1.30 0.80 2 0
Mean 0.62 4.39 2.62 0.80 1.7 1.7
CTVdiagPET 1 0.47 7.78 9.12 0.70 12 24
2 0.47 7.36 3.86 0.72 9 15
3 0.61 4.26 2.68 0.77 4 4
Mean 0.52 6.47 5.22 0.73 7.3 13.3
P-value (CTVINRT vs. CTVdiagPET) 0.001 <0.001 0.01 <0.001 – –
CTV = clinical target volume; CoG = centre of gravity distance; CI = conformality index; MDC = mean distance to conformity; Se.Idx = sensitivity index.
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larger for patient 1. For the superior CTV extent, CTVdiagPET varied
by +2 to 21 mm beyond CTVINRT. The inferior CTV extent, CTVdiagPET
varied by 27 to +12 mm. Based upon these data, there were con-
siderable discrepancies between the superior and inferior extents
of CTVdiagPET and CTVINRT; for patient 2 an additional 27 mm was
required inferiorly beyond CTVdiagPET to ensure that CTVINRT was
included.4.3. Comparison of CTVINRT and CTVdiagPET: Axial plane
Table 2 shows the positional metrics used to compare CTVINRT
and CTVdiagPET in the axial plane (data based on CTVs within over-
lapping lengths). Overall there was considerable differences
between CTVINRT and CTVdiagPET contours in the axial plane. Mean
DICE index was limited at 0.63 (range 0.61–0.65). Mean differences
in CGD was 5 mm (range 2.5–10.0). Mean Se.Idx was 0.68 (range
Table 2
CTVINRT and CTVdiagPET volumes and their variation in superior and inferior extent.
Patient Variation in superior-inferior CTV extent Comparison of CTVs in axial plane
Volume (cm3) CoG (mm)
(Sup-Inf direction)
Margins from CTVINRT to
CTVdiagPET (mm)*
CI MDC (mm) CGD (mm) DICE Se.Idx
CTVINRT CTVdiagPET Difference (%) Superior Inferior
1 67 110 +66 4.3 2 12 0.40 9.74 10.07 0.63 0.79
2 109 114 +5 3.0 21 -27 0.43 12.06 3.69 0.61 0.63
3 54 53 2 1.1 12 0 0.48 6.43 2.45 0.65 0.63
Mean 76 92 +21 2.8 9 -2 0.44 9.41 5.40 0.63 0.68
Stdev 34 29  1.6 6 15 0.04 2.83 4.09 0.02 0.09
CTV = clinical target volume; CoG = centre of gravity distance; CI = conformality index; MDC = mean distance to conformity; Se.Idx = sensitivity index.
* ‘’indicates undercontouring and ‘+’ indicates overcontouring over CTVdiagPET compared with CTVINRT.
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within CTVdiagPET in the axial plane. MDC includes both over- and
underlap of contours. Mean and maximum MDC undercoverage
(areas of undercoverage of CTVINRT by CTVdiagPET) were 4 and
16.4 mm respectively. Mean and maximum MDC overcoverage
(regions of CTVdiagPET which are non-overlapping with CTVINRT)
was 5.5 and 18.3 mm respectively.
5. Discussion
No previous studies have evaluated the CTV expansion required
for axillary radiotherapy. The treatment position FDG PET-CT in
this prospective study allows the generation of INRT CTVs which
represent a ‘gold standard’ for comparison with CTVs contoured
using non-registered diagnostic non-treatment position PET-CT.
This report aims to evaluate differences in CTVdiagPET compared
with CTVINRT to inform on appropriate CTV margin expansions
for ISRT for axillary radiotherapy.
Intra-observer variability was assessed to provide a guide to the
reproducibility CTV contouring. Variation in the cranio-caudal CTV
extent was low for CTVINRT (maximum of 3 mm superior-inferior
variation) but higher for CTVdiagPET (maximum 24 mm superiorly
and 12 mm inferiorly). Similarly, CTVINRT was significantly more
reproducible in the axial plane based on assessment of all posi-
tional metrics.
CTVINRT and CTVdiagPET were compared in craniocaudal extent
and in the axial plane. The maximum distance of ‘under-
contouring’ of the CTVdiagPET compared with the ‘gold-standard’
CTVINRT was 27 mm inferiorly. The maximum ‘over-contouring’ of
the CTVdiagPET was 21 mm superiorly and 15 mm inferiorly. There
was only limited conformality between CTVINRT and CTVdiagPET in
the axial plane, with a mean DICE of 0.63 (range 0.61–0.65). The
mean Se.Idx was 0.68 (range 0.63–0.79) meaning that in the axial
plane a mean of 68% of the CTVINRT was encompassed by the
CTVdiagPET, implying a significant risk of geographical miss with
the CTVdiagPET if an appropriate CTV expansion is not added to
account for this inaccuracy. The maximum MDC under coverage
was 16.4 mm (mean 4 mm). These data are despite modification
to anatomical boundaries and suggest a generous approach is
required in the axial plane. One patient in this study (patient 1)
had the diagnostic PET-CT with arms down due to discomfort
maintaining the arms up position. It might be considered that this
would assist in contouring the CTVdiagPET, although it is notable
that there remained considerable cranio-caudal differences and
similar positional metrics in the axial planes to the other two
patients.
These data indicate the potential inaccuracy of contouring an
axillary CTV in the absence of treatment-position PET-CT. As only
3 patients from our imaging study had axillary disease, this analy-
sis cannot explore the extent of variability in CTV contouringbetween patients with small/large volume disease and different
sites within the axilla. However, analysis shows high intra-
observer variability, considerable craniocaudal over- and under-
contouring, and limited conformality in the axial plane for
CTVdiagPET. Contouring of CTVdiagPET in patients with axillary disease
appears considerably less accurate than for neck disease based on
our prior data [6]. This is likely to relate to the large positional dif-
ferences between anatomy in the axilla depending upon arm posi-
tion and the lack of obvious anatomical landmarks by comparison
with the neck.
Our practice has been to deliver axillary radiotherapy arms
down with a 5-point thermoplastic mask which we have found
to optimise of reproducibility of shoulder/arm position and allow
simpler treatment of adjacent neck if required. Other treatment
positions are feasible e.g. arms up on a wing board which may offer
some separation of target volume from the lungs; this can match
the pre-chemotherapy arms up PET-CT position although unless
identical immobilisation devices are used positions will still differ.
Clearly these data cannot be directly applied to different treatment
positions. However, the variability shown highlights the impor-
tance attempting to obtain optimal treatment-position imaging
pre-chemotherapy. In the absence of optimal pre-chemotherapy
imaging clinical judgement is necessary in CTV construction based
upon ease in re-constructing the pre-chemotherapy extent of dis-
ease. These data demonstrate the difficulty of accurate tumour
reconstruction in the axilla and the need to carefully consider mar-
gins to avoid geographic misses.
In summary, our small cohort demonstrated that a generous
CTV expansion is required cranio-caudally and in the axial plane
to ensure the pre-chemotherapy extent of axillary disease is
encompassed. Centres should attempt to acquire pre-
chemotherapy PET-CT as close to the treatment position as possi-
ble to improve the accuracy of contouring and allow smaller CTVs.Acknowledgements
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